Kanamycin Sulfate Eye Drops

Kanamycin is an aminoglycoside antibiotic. It has a good effect on most Enterobacteriaceae, such as Escherichia coli, Klebsiella, Proteus, Enterobacter, Shigella, Salmonella, Citrobacter, Providencia, Yersinia, etc.; influenza bacillus, Brucella, meningococcus, gonococcus, etc. are also mostly sensitive to this product, and it is ineffective against Pseudomonas aeruginosa. It also has a certain effect on methicillin-sensitive strains of Staphylococcus and Mycobacterium tuberculosis. Other Gram-positive bacteria such as hemolytic streptococci, Streptococcus pneumoniae, enterococci and anaerobic bacteria are mostly resistant to this product. Kanamycin mainly binds to the 30S subunit of the bacterial ribosome and inhibits the synthesis of bacterial proteins. Kanamycin has complete cross-resistance with streptomycin and neomycin, and may have partial cross-resistance with other aminoglycosides.

The main ingredient of this product is kanamycin sulfate. It is a multi-component antibiotic containing three components A, B, and C, with A being the main ingredient.

It is suitable for the treatment of conjunctivitis, keratitis, dacryocystitis, blepharitis, tarbomitis and other infections caused by sensitive bacteria such as Escherichia coli, Klebsiella, Proteus, Neisseria gonorrhoeae and Staphylococcus.

Instill into the conjunctival sac, 1 to 2 drops at a time, 3 to 5 times a day.

Occasionally there may be mild eye irritation and discomfort, but no systemic adverse reactions.

1. It is contraindicated for those who are allergic to this product or other aminoglycosides. 2. It is used with caution by pregnant and lactating women.

Precautions during pregnancy and lactation: Use with caution in pregnant and lactating women.

1. When used in combination with other aminoglycosides or applied topically in sequence, it may increase ototoxicity, nephrotoxicity and neuromuscular blocking effects. 2. When used in combination with capreomycin, cisplatin, ethacrynic acid, furosemide or vancomycin (or norvancomycin), or applied topically in sequence, it may increase ototoxicity and nephrotoxicity. 3. When used topically with cephalothin or cefazolin, it may increase nephrotoxicity. 4. Other nephrotoxic and ototoxic drugs should be used with caution in combination or in sequence with this product to avoid aggravating nephrotoxicity or ototoxicity.

Keep tightly closed in a cool, dark place.

8ml:40mg (calculated according to C18H38N4O11)

Shanxi Liye Pharmaceutical Co., Ltd.

• Founded in:

  2017-06-26

• Address:

  No. 21, Huagong Road, Jinyuan District, Taiyuan City, Shanxi Province

• Tax NO.:

  91140100MA0HJG3U47

• Registered Funds:

  45 million yuan

• Website:

  Log in to view

• Email:

  Log in to view